Cantor Fitzgerald Slashes PT on Oncothyreon (ONTY) from $11 to $4

March 15, 2013 11:38 AM EDT Send to a Friend
Get Alerts ONTY Hot Sheet
Price: $1.77 -6.84%

Rating Summary:
    6 Buy, 2 Hold, 1 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 29 | Down: 28 | New: 24
Trade ONTY Now!
Join SI Premium – FREE
Cantor Fitzgerald today maintained a Buy rating on Oncothyreon (NASDAQ: ONTY) and cut its price target to $4.00 (from $11.00). The cut in price target relates to the loss of candidate Stimuvax (L-BLP25).

"While partner Merck (NYSE: MRK) KGaA has indicated that treatment effects were observed in sub-populations, and an abstract has been submitted to ASCO for this year, our financial model assumes that commercialization does not occur and no value for this candidate is included in our valuation," said analyst Adeyemi Ogunkoya.

For an analyst ratings summary and ratings history on Oncothyreon (NASDAQ: ONTY) click here. For more ratings news on Oncothyreon click here.

Shares of Oncothyreon closed at $2.21 yesterday.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments, Analyst EPS Change, Analyst PT Change

Related Entities

Cantor Fitzgerald

Add Your Comment